Share on LinkedInShare on LinkedIn

ARTICLE · 09 OCTOBER 2017

The Latest: Integra Forced To Divest Neurosurgical Tools To Gain FTC Clearance

On February 14, 2017, Integra agreed to purchase Johnson & Johnson's Codman neurosurgery business (excluding Codman's neurovascular and drug deliver businesses) for $1.045 billion.

United StatesAntitrust/Competition Law

WHAT HAPPENED

  • On February 14, 2017, Integra agreed to purchase Johnson & Johnson's Codman neurosurgery business (excluding Codman's neurovascular and drug deliver businesses) for $1.045 billion.
  • Seven months later, on September 25, 2017, the Federal Trade Commission (FTC) agreed to clear the transaction subject to the parties divesting five neurosurgical tools and associated assets including the relevant intellectual property (IP), manufacturing technology and know-how, and research & development (R&D) information related to the five tools. Additionally the buyer of the divested assets can freely negotiate to hire any employees that worked on sales, marketing, manufacturing, or R&D for the divestiture products. The parties must also supply Natus Medical Incorporated (Natus) with cranial access kits often sold with the divestiture assets until Natus can start sourcing them independently.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from